|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1025 Connecticut Ave. |
Address2 | #1005 |
| City | Washington |
State | DC |
Zip Code | 20036-5405 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401110446-71834
|
||||||||
|
6. House ID# 774780001
|
||||||||
| TYPE OF REPORT | 8. Year | 2026 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Tyler McGee |
Date | 4/20/2026 8:43:14 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code GOV
16. Specific lobbying issues
Communications with United States Senate offices and federal executive branch officials on behalf of Dr. Jose M. Wiley, MD, MPH, FACC, FSCAI, regarding federal health policy priorities and federal health agency matters. Engagement during the reporting period included meetings and communications with Senate offices on matters within the jurisdiction of the Senate Committee on Health, Education, Labor, and Pensions and the Senate Committee on Veterans Affairs; communications with officials at the Department of Health and Human Services regarding federal health policy priorities and potential positioning of Dr. Wiley for federal health engagement; written outreach to officials at the National Institutes of Health regarding federal health leadership matters and Dr. Wileys potential service in a senior federal health leadership capacity; and written outreach to the National Economic Council within the Executive Office of the President regarding healthcare economics, pharmaceutical pricing policy, and Dr. Wileys potential contribution to federal health policy deliberations. Policy discussions addressed chronic disease prevention, cardiovascular health, metabolic health, pharmaceutical pricing and pharmacy benefit manager reform, veterans health, nutrition and food policy, military medical readiness, and federal health agency reform. Specific legislation referenced during these communications included S.1587, the Fair Prescription Drug Prices for Americans Act; S.3822, the Break Up Big Medicine Act; S.1816, the Improving Seniors Timely Access to Care Act of 2025; S.3299, the DSH in Tennessee Act; and S.500, the CAREER Act of 2025. The engagement is framed around Dr. Wileys clinical expertise as a cardiologist, his academic and health system leadership, and his service as a Lieutenant Colonel in the United States Army Reserve, positioning his experience as a resource for federal health policymakers pursuing the priorities reflected in the administrations health reform agenda. The Senate office communications were collaborative and policy-oriented in nature, focused on shared legislative priorities in chronic disease prevention, veterans health, and federal health agency performance. No substantive meeting or advocacy regarding a specific Senate-confirmed position occurred during the reporting period.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, Natl Institutes of Health (NIH), Executive Office of the President (EOP), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tyler |
McGee |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |